ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last721 to 740 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants With at Least One Serious Adverse Event (SAE)263 of 6,352

266 of 6,366

-0.0 points

-0.7 to 0.7

12,718NCT03739112

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants With Unsolicited Treatment-Emergent Adverse Events (TEAEs)849 of 6,352

824 of 6,366

0.4 points

-0.8 to 1.6

12,718NCT03739112

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Occurrences of Death12 of 6,352

17 of 6,366

-0.1 points

-0.3 to 0.1

12,718NCT03739112

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants Who Withdrew Due to an AE15 of 6,352

20 of 6,366

-0.1 points

-0.3 to 0.1

12,718NCT03739112

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants With at Least One New Onset Chronic Diseases (NOCDs)36 of 6,352

23 of 6,366

0.2 points

-0.0 to 0.5

12,718NCT03739112

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants With ≥ Severe Solicited Local and Systemic Reaction47 of 6,352

62 of 6,366

-0.2 points

-0.6 to 0.1

12,718NCT03739112

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants With at Least One Immediate Complaints272 of 6,352

184 of 6,366

1.4 points

0.7 to 2.0

12,718NCT03739112

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants With ≥ Severe Related Unsolicited Reactions1 of 6,352

3 of 6,366

-0.0 points

-0.1 to 0.0

12,718NCT03739112

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants With ≥ Severe Related Solicited Reactions28 of 6,352

51 of 6,366

-0.4 points

-0.6 to -0.1

12,718NCT03739112

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants With ≥ Severe Unsolicited TEAEs33 of 6,352

34 of 6,366

-0.0 points

-0.3 to 0.2

12,718NCT03739112

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): deaths from any cause12 of 6,352

17 of 6,366

-0.1 points

-0.3 to 0.1

12,718NCT03739112

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): serious adverse events263 of 6,352

266 of 6,366

-0.0 points

-0.7 to 0.7

12,718NCT03739112

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

Patients Screened for HIV vs Patients Screened for HCV: Opt-out1,479 of 6,350

1,487 of 6,350

-0.1 points

-1.6 to 1.3

12,700NCT03595527

Universal HIV Screening and Targeted HCV Screening in Emergency Department

Conventional EMS CPR vs Bundled EMS CPR: Number of Participants With Survival to Hospital Discharge594 of 6,201

707 of 6,469

-1.3 points

-2.4 to -0.3

12,670NCT02540629

Implementation of Gold Standard EMS CPR Programs for 2% Improvement in Survival Rates of Out-of-Hospital Cardiac Arrest in a Metropolitan City

Conventional EMS CPR vs Bundled EMS CPR: Number of Participants With Good Neurological Recovery at Discharge334 of 6,201

441 of 6,469

-1.4 points

-2.3 to -0.6

12,670NCT02540629

Implementation of Gold Standard EMS CPR Programs for 2% Improvement in Survival Rates of Out-of-Hospital Cardiac Arrest in a Metropolitan City

Conventional EMS CPR vs Bundled EMS CPR: deaths from any cause5,607 of 6,201

5,762 of 6,469

1.3 points

0.3 to 2.4

12,670NCT02540629

Implementation of Gold Standard EMS CPR Programs for 2% Improvement in Survival Rates of Out-of-Hospital Cardiac Arrest in a Metropolitan City

Acetylsalicylic Acid vs Placebo: serious adverse events1,266 of 6,270

1,311 of 6,276

-0.7 points

-2.1 to 0.7

12,546NCT00501059

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

Insulin Glargine vs Standard Care: Total Mortality (All Causes)951 of 6,264

965 of 6,273

-0.2 points

-1.5 to 1.1

12,537NCT00069784

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

Insulin Glargine vs Standard Care: Number of Patients With First Occurrence of Any Type of Cancer559 of 6,264

561 of 6,273

-0.0 points

-1.0 to 1.0

12,537NCT00069784

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

E-MOTIVE Intervention vs Usual Care: Compliance With MOTIVE Bundle3,791 of 4,158

1,623 of 8,351

71.7 points

70.5 to 72.9

12,509NCT04341662

A Clinical Trial to Study the Effectiveness of a Care Bundle to Prevent Bleeding After a Woman Has Given Birth

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=37

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03739112-13c037c8",
        "title": "Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants With at Least One Serious Adverse Event (SAE)",
        "summary": "263 of 6352 against 266 of 6366; risk difference -0.0 points, 95% interval -0.7 to 0.7; NCT03739112, Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly",
        "record": "/library/comparisons/NCT03739112-13c037c8",
        "nct_id": "NCT03739112",
        "kind": "outcome",
        "participants": 12718,
        "risk_difference": {
          "value": -0.00038019793439802996,
          "lower": -0.007340194565206024,
          "upper": 0.006579711871167111
        },
        "group_1": "263 of 6,352",
        "group_2": "266 of 6,366",
        "difference": "-0.0 points",
        "interval": "-0.7 to 0.7",
        "trial_title": "Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly"
      },
      {
        "id": "NCT03739112-4e5f9fb1",
        "title": "Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants With Unsolicited Treatment-Emergent Adverse Events (TEAEs)",
        "summary": "849 of 6352 against 824 of 6366; risk difference 0.4 points, 95% interval -0.8 to 1.6; NCT03739112, Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly",
        "record": "/library/comparisons/NCT03739112-4e5f9fb1",
        "nct_id": "NCT03739112",
        "kind": "outcome",
        "participants": 12718,
        "risk_difference": {
          "value": 0.0042210527273748855,
          "lower": -0.007531375116861071,
          "upper": 0.015975191767790997
        },
        "group_1": "849 of 6,352",
        "group_2": "824 of 6,366",
        "difference": "0.4 points",
        "interval": "-0.8 to 1.6",
        "trial_title": "Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=38",
  "request_id": "Vchb3TXi6wJ0OOuA"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?